Substituted aminothiazoles as DGKzeta inhibitors for immune activation

US11964953B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• Deutsches Krebsforschungszentrum · DE

Inventors

• Norbert Schmees · Berlin, DE
• Ulrike Roehn · Berlin, DE
• Dennis KIRCHHOFF · Berlin, DE
• Kirstin Petersen · Berlin, DE
• Mareike GREES · Berlin, DE
• Nicolas Werbeck · Berlin, DE
• Benjamin Bader · Berlin, DE
• Rienk Offringa · Leiden, NL
• Corinna LINK · Heidelberg, DE

Key dates

• Filing date: Sep 14, 2022
• Grant date: Apr 23, 2024
• Expiry date: Sep 14, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/07
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention covers aminothiazole compounds of general formula (I), in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGKζ) regulated disorders, as a sole agent or in combination with other active ingredients.